Inside informationEnglish
Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data ? Randomization to be Completed in Phase II Part in Q4 2025
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Transgene S.A.
- Filed
- 16/09/2025, 17:45
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 118311_20250916